Trial Profile

A Phase 1/2 Multicenter, Open-Label, Dose-escalation and Expansion Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TTX-MC138 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors TransCode Therapeutics

Most Recent Events

03 Jun 2026 According to a TransCode Therapeutics media release, company announced further results of the Phase 1a dose escalation clinical trial.
03 Jun 2026 Results presented in the TransCode Therapeutics Media Release.
14 Nov 2025 According to a TransCode Therapeutics media release, preliminary data to be presented in a poster session at ESMO Congress October 17-21, 2025, taking place in Berlin, Germany. (FPN: 983P)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com